Fish oil will be administered to this group. We will administer 4g per day of fish oil in three times with meals for one month with monitoring the health status regularly

Ischemic Stroke

Neurological Injury

Stroke, Acute

Inflammatory Response

Permanent Injury

Neurologic Dysfunction

Neurological Disorder

Brain Ischemia

Brain Injuries

Omega-3 fish oil

Omega 3 and Ischemic Stroke; Fish Oil as an Option

The Potential Effect of Omega3 Supplement in Fish Oil on Infarced Areas in the Brain and Improvement of Neurological Functions fo Ischemic Stroke Patients

will be assessed by square centimetres on MRI scan

Assessed by National Institutes of Health Stroke Scale. The scale range is from 0 to 42 as following:
0 No stroke symptoms
1-4 Minor stroke
5-15 Moderate stroke
16-20 Moderate to severe stroke
21-42 Severe stroke

Assessed by the modified Rankin Scale. The scale consists of degrees from 0 to 6 as following:
0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability
- Moderate disability.
- Moderately severe disability
- Severe disability
- Dead.

Nouf Al Mansour

Subspecialty Consultant Neurologist And Stroke Specialist

King Fahad Medical City

Gluten powder (10 g every 12 hours), 24 weeks

Placebo (maltodextrin; 10 g every 12 hours), 24 weeks

Celiac Disease

Non-celiac Gluten Sensitivity

gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet

Gluten challenge

placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet

Placebo challenge

Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo

Lymphocytic Enteritis and Suspected Coeliac Disease: Double-blind Gluten vs Placebo Rechallenge

Visual analogue scale on clinical symptoms at each visit (Baseline, 4 weeks, 12 weeks, 24 weeks)

GI quality of life index (GIQLI) at basal and 24 week visits

Changes in intraepithelial lymphocyte count

Changes in cytometric count of gamma/delta cells

Fernando Fernandez-Bañares

Hospital Mutua de Terrassa

Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds

50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)
55 to <60 30 mg 6 ml
60 to <70 35 mg 7 ml
70 to <80 40 mg 8 ml
80 to <90 45 mg 9 ml
90 50 mg 10 ml

Myocardial Infarction

15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds

Recombinant staphylokinase

50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)
55 to <60 30 mg 6 ml
60 to <70 35 mg 7 ml
70 to <80 40 mg 8 ml

Tenecteplase

ESC/EACTS Guidelines in Myocardial Revascularisation

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

Efficacy Guidelines. The work carried out by ICH under the Efficacy heading is concerned with the design, conduct, safety and reporting of clinical trials.

Institute of Cardiology

St. Iosaf`s Belgorod Regional Clinical Hospital

Kemerovo cardiological dispensary

Research Institute of Complex Problems of Cardiovascular diseases

City Clinical Hospital #11

Russian national research medical University named after Pirogov

City Clinical Hospital #81

The Sklifosovsky Research institute of Emergency

Murmansk Regional Clinical Hospital

City Clinical Hospital #5

Regional Clinical Hospital

Samara Regional Clinical Cardiological Dispansery

Mariinsk City Hospital

Leningrad Regional Clinical Hospital

City Clinical Hospital of Emergency #25

Single Bolus Recombinant Nonimmunogenic Staphylokinase (FORtelyzin) Versus Single Bolus Tenecteplase (Metalyse) in STEMI

Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients

ST-segment resolution is ≥ 50 % in the qualifying lead (that had the maximum initial ST-segment elevation in the baseline ECG) in 90 min;
TIMI 2-3 or TFC 25-40 frames (for TIMI 3) and 41-60 frames (for TIMI 2) by coronary angiography

Death caused by any cardiovascular reason/event

The need for re-intervention on infarct-related artery within 30 days after fibrinolysis

In case of at least of the one of the following conditions:
Pulmonary oedema/congestion on chest X-ray without suspicion of a non-cardiac cause
Rales > 1/3 up from the lung base (Killip class 2 or higher)
Pulmonary capillary wedge pressure (PCWP) >25 mmHg
Dyspnoea with pO2 < 80 mmHg or O2 sat < 90 % (no supplemental O2) in the absence of known lung disease;

acetylsalicylic acid/atrophy

Omega 3 and Ischemic Stroke; Fish Oil as an Option

Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo

Single Bolus Recombinant Nonimmunogenic Staphylokinase (FORtelyzin) Versus Single Bolus Tenecteplase (Metalyse) in STEMI

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht